Pancreatic cancer organoids recapitulate disease and allow personalized drug screening
- 9 December 2019
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 116 (52), 26580-26590
- https://doi.org/10.1073/pnas.1911273116
Abstract
We report the derivation of 30 patient-derived organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical of pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic, and underscores the importance of personalized approaches for effective cancer treatment. The PRMT5 inhibitor EZP015556, shown to target MTAP (a gene commonly lost in pancreatic cancer)-negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP-positive tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.Keywords
Funding Information
- American Association for Cancer Research (SU2C-AACR-DT1213)
- ZonMw (116.006.103)
- Welcome Trust (206194)
- CRUK (C44943/A22536)
- Dutch Digestive foundation (MLDS CDG 14-020)
This publication has 38 references indexed in Scilit:
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineThe New England Journal of Medicine, 2013
- Deregulation of protein methylation in melanomaEuropean Journal of Cancer, 2013
- Mutant p53: one name, many proteinsGenes & Development, 2012
- Versatility of PRMT5-induced methylation in growth control and developmentTrends in Biochemical Sciences, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Direct and tumor microenvironment mediated influences of 5′‐deoxy‐5′‐(methylthio)adenosine on tumor progression of malignant melanomaJournal of Cellular Biochemistry, 2008
- A Transition State Analogue of 5′-Methylthioadenosine Phosphorylase Induces Apoptosis in Head and Neck CancersOnline Journal of Public Health Informatics, 2007
- Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-α1, interferon-β1, and other 9p21 markers in human malignant cell linesCancer Genetics and Cytogenetics, 1996
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993